Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of Long-acting Depot Buprenorphine (LADB) for the Treatment of Opioid Dependence in Low- and Middle-income Countries (LMIC): a Multicentre International Study

NCT06129916 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT06129916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06129916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of Long-acting Depot Buprenorphine (LADB) for the Treatment of Opioid Dependence in Low- and Middle-income Countries (LMIC): a Multicentre International Study
Lead sponsor
PATH
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2025
Completion date
June 30, 2027
Enrollment
760 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

opioid dependence